Smallpox in the 21st Century

Anesthesiology Clinics of North America

Volumn 22, Issue 3, 2004, Pages 541-561

  Lupatkin, Helene ^a   Lupatkin, Joel F ^b   Rosenberg, Andrew D ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DYRAX VACCINE; METISAZONE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA ANTIBODY; VACCINIA VACCINE; VIRUS VACCINE;

ALASTRIM; ANAPHYLAXIS; ASEPTIC MENINGITIS; CELLULITIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULARY; ECZEMA; ENDEMIC DISEASE; ERYTHEMA MULTIFORME; EYE INFECTION; FATALITY; FOLLICULITIS; GOVERNMENT; HEALTH CARE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; INFECTION PREVENTION; INFECTION RISK; INOCULATION; NONHUMAN; OCCUPATIONAL SAFETY; OUTPATIENT DEPARTMENT; PATHOGENESIS; PRACTICE GUIDELINE; PUBLIC HEALTH; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SMALLPOX; SMALLPOX VIRUS; STATISTICAL SIGNIFICANCE; STEVENS JOHNSON SYNDROME; VACCINATION; VACCINIA; VACCINIA VIRUS; VIRION; VIRUS ISOLATION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

HUMANS; SMALLPOX; SMALLPOX VACCINE; VACCINATION;

EID: 4344718622     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atc.2004.05.001     Document Type: Review

References (57)

1. Fenner F., Henderson D.A., Arita L., Jezek Z., Ladnyi I.D. Smallpox and its eradication. 1988;137 World Health Organization, Geneva, Switzerland
2. Henderson D.A., Inglesby T.V., Bartlett J.G., Ascher M.S., Eitzen E., Jahrling P.B., et al. Smallpox as a biological weapon. JAMA. 281:1999;2127-2137
3. WHO Health Assembly March 2003 Smallpox eradication: destruction of variola virus stocks. Available at: http://www.who.int/gb/EB_WHA/PDF/WHA56/ ea5614.pdf. Accessed January 10, 2004
4. Eyler J.M. Smallpox in history: the birth, death, and impact of a dread disease. J Lab Clin Med. 142:2003;216-220
5. Boylstom A.W. Clinical investigaton of smallpox in 1767. N Engl J Med. 346:2002;1326-1328
6. Jenner E. An inquiry into the causes and effects of the variolae vaccinae: a disease discovered in some of the western counties of England, particulary Gloucestershire, and known by the name of the cow pox. 1978;Classics of Medicine Library, Birmingham, Alabama
7. Rao A.R. Smallpox. 1972;Kothari Book Depot, Bombay, India
8. McKenzie P.J., Githens J.H., Harwood M.E., Roberts J.F., Rao A.R., Kempe C.H. Haemorrhagic smallpox. Bull World Health Organ. 33:1965;773-782
9. Breman J.G., Henderson D.A. Diagnosis and management of smallpox. N Engl J Med. 346:2002;1300-1308
10. Centers for Disease Control and Prevention Guide D. Specimen collection guidelines. 2002. Available at: http://www.bt.cdc.gov/agent/smallpox/response- plan/files/guide-d.pdf. Accessed January 10, 2004
11. Centers for Disease Control and Prevention Draft Guide C. Infection control measures for healthcare and community settings. 2003. Available at: http://www.bt.cdc.gov/agent/smallpox/response-plan/files/guide-c-part-1.pdf. Accessed January 10, 2004
12. Rao A.R., McFadzean J.A., Kamalakshi K. An isothiazole thiosemicarbazone in the treatment of variola major in man. Lancet. 1:1966;1068-1072
13. Neyts J., De Clercq E. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res. 57:2003;25-33
14. Neyts J., De Clercq E. Efficacy of (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol. 41:1993;242-246
15. Winegarden K.L., Ciesla S.L., Aldern K.A., Beadle J.R., Hostetler K.Y. Oral pharmacokinetics and preliminary toxicology of 1-O-hexadecyloxypropyl- cidofovir in mice. Abstracts of the 15th International Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002. Antiviral Res. 53:2002;A67
16. Bray M., Martinez M., Kefauver D., West M., Roy C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res. 54:2002;129-142
17. Gruchalla R.S., Jones J. Combating high-priority biological agents: what to do with drug allergic patients and those for who vaccination is contraindicated? J Allergy Clin Immunol. 112:2003;675-682
18. Kempe C.H., Bowles C., Meiklejohn G., Berge T.O., St. Vincent L., Babu B.V., et al. The use of vaccinia hyperimmune gamma-globulin in the prophylaxis of smallpox. Bull World Health Organ. 25:1961;41-48
19. Ramirez J.C., Tapia E., Esteban M. Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol. 83:2002;1059-1067
20. Frey S.E., Couch R.B., Tacket C.O., Treanor J.J., Wolff M., Newman F.K., et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med. 346:2002;1265-1274
21. st-century risks of smallpox vaccination and policy options. Ann Intern Med. 138:2003;488-493
22. Health Resources and Services Administration US Department of Health and Human Services Smallpox vaccine injury compensation program. Available at: http://www.hrsa.gov/smallpoxinjury/. Accessed January 10, 2004
23. Bartlett J., Borio L., Radonovich L., Mair J.S., O'Toole T., Mair M., et al. Smallpox vaccination in 2003: key information for clinicians. Clin Infect Dis. 36:2003;883-902
24. Kuhles D.J., Ackman D.M. The federal smallpox vaccination program: where do we go from here? Health Affairs Web Exclusive (Millwood). W3:2003;503-510. Available at http://www.healthaffairs.org. Accessed January 10, 2004
25. Centers for Disease Control and Prevention Smallpox vaccination and adverse reactions: guidelines for clinicians. MMWR Recomm Rep. 52(RR-4):2003;1-29
26. Plotkin S.A., Orenstein W.A. Vaccines. 4th edition:2004;WB Saunders, Philadelphia
27. Lane J.M., Ruben F.L., Neff J.M., Millar J.D. Complications of smallpox vaccination, 1968: national surveillance in the United States. N Engl J Med. 281:1969;1201-1208
28. Lane J.M., Ruben F.L., Neff J.M., Millar J.D. Complications of smallpox vaccination, 1968: results of ten state wide surveys. J Infect Dis. 122:1970;303-309
29. Haim M., Gdalevich M., Mimouni D., Ashkenazi I., Shemer J. Adverse reactions to smallpox vaccine: the Israeli Defense Force experience, 1991 to 1996. A comparison with previous surveys. Mil Med. 165:2000;287-289
30. Grabenstein J.D., Winkenwerder W. Jr. US military smallpox vaccination program experience. JAMA. 289:2003;3278-3282
31. Centers for Disease Control and Prevention Adverse events associated with smallpox vaccination among civilians. Total number of cases (Jan 24-Nov 30,2003). Available at: http://www.cdc.gov/od/oc/media/spcivil.htm. Accessed January 10, 2004
32. United States Department of Defense Panels find vaccines may relate to reservists illness, death. News release. Available at: http://www.defenselink. mil/releases/2003/nr20031119-0656.html. Accessed January 10, 2004
33. Neff J.M., Lane J.M., Fulginiti V.A., Henderson D.A. Contact vaccinia-transmission of vaccinia from smallpox vaccination. JAMA. 288:2002;1901-1905
34. Ruben F.L., Lane J.M. Ocular vaccinia: an epidemiologic analysis of 348 cases. Arch Ophthalmol. 84:1970;45-48
35. Pepose J.S., Margolis T.P., LaRussa P., Pavan-Langston D. Ocular complications of smallpox vaccination. Am J Ophthalmol. 136:2003;343-352
36. Munns G.F. Accidental vaccination of the eyelids. Am J Ophthalmol. 14:1931;1037-1039
37. Story J.B. Vaccination of the cornea. BMJ. 1:1907;346
38. Pavan-Langston D. Ocular viral infections. Med Clin North Am. 67:1983;973-990
39. Fulginiti V.A., Winograd L.A., Jackson M., Ellis P. Therapy of experimental vaccinial keratitis. Arch Ophthalmol. 74:1965;539-544
40. Goldstein V.A., Neff J.M., Lane J.M., Koplan J.P. Smallpox vaccination reactions, prophylaxis and therapy of complications. Pediatrics. 55:1975;342-347
41. Talbot T.R., Bredenberg H.K., Smith M., La Fleur B.J., Boyd A., Edwards K.M. Focal and generalized folliculitis following smallpox vaccination among vaccinia-naïve recipients. JAMA. 289:2003;3290-3294
42. Copeman P.W.M., Wallace H.J. Eczema vaccinatum. BMJ. 2:1964;906-908
43. Engler R.J.M., Kenner J., Leung D.Y.M. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J Allergy Clin Immunol. 110:2002;357-365
44. Kempe C.H. Studies on smallpox and complications of smallpox vaccination. E. Mead Johnson Award address. Pediatrics. 26:1960;176-189
45. Bray M., Wright M.E. Progressive vaccinia. Clin Infect Dis. 36:2003;766-774
46. De Vries E. Postvaccinial perivenous encephalitis. 1960;Elsevier, Amsterdam
47. Green D.M., Reid S.M., Rhaney K. Generalised vaccinia in the human foetus. Lancet. 1:1966;1296-1298
48. Halsell J.S., Riddle J.R., Atwood J.E., Gardner P., Shope R., Poland G.A., et al. Myopericarditis following smallpox vaccination among vaccinia-naïve US military personnel. JAMA. 289:2003;3283-3289
49. Murphy J.G., Wright R.S., Bruce G.K., Baddour L.M., Farrell M.A., Edwards W.D. Eosinophilic-lymphocytic myocarditis after smallpox vaccination. Lancet. 362:2003;1378-1380
50. Centers for Disease Control and Prevention Notice to readers: supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 52:2003;282-284
51. Centers for Disease Control and Prevention Update: cardiac-related events during the civilian smallpox vaccination program - United States, 2003. MMWR Morb Mortal Wkly Rep. 52:2003;492-496
52. Weltzin R., Liu J., Pugachev K.V., Myers G.A., Coughlin B., Blum P.S., et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med. 9:2003;1125-1130
53. Blanchard T.J., Alcami A., Andrea P., Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implication for use as a human vaccine. J Gen Virol. 79:1998;1159-1167
54. Drexler I., Staib C., Kastenmuller W., Stevanovic S., Schmidt B., Lemonnier F.A., et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci USA. 100:2003;217-222
55. Wyatt L.S., Earl P.L., Eller L.A., Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA. 101:2004;4590-4595
56. Earl P.A., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature. 428:2004;182-185
57. Clinical Trials Phase I/II trial of modified vaccinia virus Ankara (MVA) vaccine against smallpox. Available at: http://clinicaltrials.gov/ct/search? term=smallpox&submit=Search. Accessed January 10, 2004